ADXN
Addex Therapeutics Ltd
Addex Therapeutics (ADXN) Q1 2026 earnings
Published Jun 25, 2026
AI summary
- GAAP EPS −CHF 0.01, unchanged from −CHF 0.01 a year ago.
- Addex Therapeutics reported no revenue for the first quarter of 2026, consistent with the prior year period.
- The company recorded a net loss of 1.71 million CHF for the quarter, compared to a 1.47 million CHF loss last year.
- Operating costs decreased to 0.49 million CHF from 0.68 million CHF in the same period of 2025.
- The company's cash and cash equivalents declined to 0.94 million CHF as of March 31, 2026.
Results vs analyst consensus
Revenue
Not reported in this release.
EPS · GAAP
Reported · GAAP diluted EPS
−CHF 0.01
Consensus not captured before release
Prior year: −CHF 0.01
Consensus: Yahoo Finance · Q1 2026
Revenue display rounded; difference uses exact result.
Next quarter outlook
No guidance in this release.
What to watch
- Management stated that substantial doubt exists regarding the company's ability to continue as a going concern.
- Existing cash is expected to fund operations only through the end of July 2026, necessitating additional capital.
Read original report
Source: Addex Therapeutics Ltd press release · SEC Form 6-K exhibit 99.1